A lymphedema screening program should be integrated into the standard management of breast cancer patients before and after locoregional and systemic therapy, according to recently published practice guidelines on the use of bioimpedance spectroscopy (BIS) for assessing breast cancer–related lymphedema (BCRL).
“The diagnosis and management of BCRL is not standardized,” said Frank A. Vicini, MD, FACR, a clinical professor and the chief academic officer at Michigan Healthcare